bluuebunny/crossref_metadata_2025_split huggingface dataset:
‘… They're talking to you as if they're kind of dumbing it down’: A thematic analysis of Black students' perceived reasons for the university awarding gap
Authors: Marandure Blessing N. , Hall Jess , Noreen Saima 
Published: January 2024

AbstractIt is widely acknowledged that there is an awarding gap in higher education, with proportionally more White students achieving a good honours degree compared to their minoritized ethnic counterparts. Furthermore, the gap is largest between Black and White students, hence necessitating initiatives to understand the perspectives of Black students on perceived reasons for the awarding gap. Thus, the present study aimed to explore the perspectives of Black undergraduate Psychology students through the use of qualitative methodology. Sixteen participants took part in two focus groups, which were transcribed verbatim, and thematic analysis was employed to analyse the data. Self‐determination theory provided a framework for contextualising the findings. Three main themes emerged, with participants describing being exposed to signals of unbelonging such as negative racial stereotypes and microaggressions. Within this theme, they discussed their responses to these signals of unbelonging, such as conforming to perceived White norms in an effort to belong and feel ‘normal’. Participants also highlighted the role played by parental influence and relationships on their academic experience. They also discussed experiences with university tutors that were deemed unfavourable. Together, the racialised experiences identified threatened the fulfilment of their needs for competence, autonomy and relatedness. It is thus imperative that higher education institutions actively engage their Black and minoritized ethnic students in order to understand their experiences and foster a sense of belonging at university. Furthermore, the findings regarding parental influence provide an opportunity for structural redress through widening participation efforts and adequate pastoral support.
openLAB – Eine Forschungsbrücke zur Entwicklung eines digitalen Brückenzwillings
Authors: Herbers Max , Bartels Jan‐Hauke , Richter Bertram , Collin Fabian , Ulbrich Lisa , Al‐Zuriqat Thamer , Chillón Geck Carlos , Naraniecki Hubert , Hahn Oliver , Jesse Frank , Smarsly Kay , Marx Steffen 
Published: January 2024

AbstractIm Rahmen des Forschungsprojekts IDA‐KI wird eine Forschungsbrücke (openLAB) gebaut, die bis in den Bereich der starken Schädigung belastet wird. Begleitend werden umfangreiche Messungen und Untersuchungen durchgeführt und somit eine einmalige Datenbasis für die Validierung von Schadensdetektions‐ und Auswertemethoden unter realen Umweltbedingungen am großmaßstäblichen Modell geschaffen. Im vorliegenden Beitrag wird die Projektidee skizziert und die im Bau befindliche Forschungsbrücke sowie das dort installierte Monitoringsystem vorgestellt. Es werden Methoden für eine automatisierte Datenauswertung und Fehlererkennung in Monitoringdaten präsentiert, die anhand der Belastungsversuche am openLAB validiert werden sollen. Erste Messungen während des Herstellungsprozesses der Fertigteile unterstreichen die Potenziale von verteilten faseroptischen Sensoren für ein Monitoring ab „Stunde null“. Relevante Informationen aus dem Bau und Betrieb der Brücke werden in einem digitalen Modell bereitgestellt. Die Konzeptionierung des sogenannten As‐maintained‐Modells sowie das Datenmanagement werden vorgestellt.
Reviewing the process intensification landscape through the introduction of a novel, multitiered classification for downstream processing
Authors: Crowley Louis , Cashen Paul , Noverraz Marc , Lobedann Martin , Nestola Piergiuseppe 
Published: January 2024

AbstractA demand for process intensification in biomanufacturing has increased over the past decade due to the ever‐expanding market for biopharmaceuticals. This is largely driven by factors such as a surge in biosimilars as patents expire, an aging population, and a rise in chronic diseases. With these market demands, pressure upon biomanufacturers to produce quality products with rapid turnaround escalates proportionally. Process intensification in biomanufacturing has been well received and accepted across industry based on the demonstration of its benefits of improved productivity and efficiency, while also reducing the cost of goods. However, while these benefits have been shown empirically, the challenges of adopting process intensification into industry remain, from smaller independent start‐up to big pharma. Traditionally, moving from batch to a process intensification scheme has been viewed as an “all or nothing” approach involving continuous bioprocessing, in which the factors of complexity and significant capital costs hinder its adoption. In addition, the literature is crowded with a variety of terms used to describe process intensification (continuous, periodic counter‐current, connected, intensified, steady‐state, etc.). Often, these terms are used inappropriately or as synonyms, which generates confusion in the field. Through a detailed review of current state‐of‐the‐art systems, consumables, and process intensification case studies, we herein propose a defined approach in the implementation of downstream process intensification through a standardized nomenclature and viewing it as distinct independent levels. These can function separately as intensified single‐unit operations or be built upon by integration with other process steps allowing for simple, incremental, cost‐effective implementation of process intensification in the manufacturing of biopharmaceuticals.
Reinforcing green business strategies with Industry 4.0 and governance towards sustainability: Natural‐resource‐based view and dynamic capability
Authors: Alkaraan Fadi , Elmarzouky Mahmoud , Hussainey Khaled , Venkatesh V. G. , Shi Yangyan , Gulko Nadia 
Published: January 2024

AbstractThe study explores the influence of contextual factors surrounding production planning and green strategic investment decision‐making practices (GSIDMP) in UK companies. We utilize a mixed‐method approach as a research methodology to study the current trend of production planning and GSIDMP. This study's conceptual model is rooted conspicuously in the resource‐based theory (RBT), natural‐resource‐based view, and dynamic capabilities. We empirically examine the nexus among GSIDMP, technological innovation, dynamic capability, and companies' performance. Our study was based on a sample selected from UK‐listed companies, FTSE ALL‐Share Index for the period (2012–2021). Also, the study utilizes data from the UK Innovation Survey (2018–2020) and corporate disclosure through companies' annual reports as a complementary approach for data collection. Findings of this study explore the interdependencies among company dynamic capability, advanced technological innovation and governance mechanisms, and their mediation influence on the nexus between GSIDMP and companies' performance. This study sheds lights on current business innovation strategies. Findings reveal how current practices of production planning and GSIDM in large UK companies shaped by boardrooms absorptive and adaptive capabilities, knowledge‐generating and knowledge‐collaboration capabilities, technological adoption, and corporate governance mechanisms. This study offers insight regarding boardrooms proactive engagement in exploration and exploitation activities to strengthen ambidexterity through various innovation trajectories associated with green production and GSIDMP towards sustainability. We provide managerial implications for decision‐makers, regulators, investors, scholars, and other stakeholders.
A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy
Authors: Zhao Yuguang , Chen Xiao , Yao Jun , Long Jianlin , Mao Yong , Wu Di , Zang Aimin , Zhao Jun , Liu Ziling , Meng Rui , Chen Ye , Luo Yang , Guo Qun , Li Li , Cui Jiuwei 
Published: January 2024

AbstractBackgroundThe development of immune checkpoint inhibitors has made a significant breakthrough in the treatment of non‐small‐cell lung cancer (NSCLC). However, there remains a huge unmet clinical need for patients with acquired resistance after initial treatment response.MethodsThis study evaluated the combination of IBI310 (an anti‐cytotoxic T lymphocyte‐associated antigen‐4 [CTLA‐4] antibody) and sintilimab (an anti‐programmed death 1 [PD‐1]) antibody) in NSCLC patients who have previously been treated with anti‐PD‐1/ligand (L)1 and acquired resistance. The patients were randomly assigned to receive either a lower dose of IBI310 (1 mg/kg Q3W, cohort A) or a higher dose of IBI310 (3 mg/kg Q3W, cohort B) in combination with sintilimab (200 mg Q3W). The primary endpoints of the study were objective response rate (ORR) assessed by RECISTv1.1 and safety, while secondary endpoints included disease control rate (DCR), progression‐free survival (PFS), and overall survival (OS).ResultsAs of November 2, 2023, the study had enrolled 30 patients, with 15 patients in each cohort. The ORR was 13.3% (2/15, 95% confidence interval [CI], 1.7–40.5) in cohort B. DCR were 46.7% (95% CI, 21.3–73.4) and 66.7% (95% CI, 38.4–88.2) in cohorts A and B, respectively. In cohorts A and B of this trial, the median follow‐up times were 4.2 and 5.6 months, respectively. Median PFS was 1.45 (95% CI, 1.35–2.73) versus 2.73 (95% CI, 1.41–4.90) months for cohort A versus B; the median OS was 7.03 (95% CI, 3.09–not calculable [NC]) months in cohort A and 8.90 (95% CI, 5.13–NC) months in cohort B. Of the 30 patients, 86.7% in both cohorts experienced treatment‐related adverse events (TRAEs) with Grade ≥3 TRAEs occurring in 40% and 53.3% of patients in cohorts A and B, respectively.ConclusionIBI310 3 mg/kg Q3W plus sintilimab was effective in a small number of previously treated anti‐PD‐1/L1‐resistant NSCLC patients.
Investigating the academic attainment and progress of children in receipt of individual counselling: A matched comparison study of primary school age children in England
Authors: Toth Katalin , Golden Sarah , Sammons Pam 
Published: January 2024

AbstractIntroductionIn 2016, the UK government identified the need for counselling services in schools to be evidence‐based (Department for Education, 2016). While there is more empirical evidence on counselling and improvement in mental health (Daniunaite et al., Counselling and Psychotherapy Research, 2015, 15, 251; Finning et al., European Child & Adolescent Psychiatry, 2022, 31, 1591), less is known about the associations of counselling with children's academic attainment and progress.MethodThe aim of the paper was to provide more pieces of evidence on the possible associations between school‐based individual counselling and the academic attainment and progress of primary school–aged children. The academic outcomes of children receiving one‐to‐one counselling were compared with those of children who did not receive counselling, but who had similar background characteristics. Coarsened exact matching method was used to match similar children for these comparisons based on national data sets available in England. Data were analysed with inferential statistics and multilinear regression.FindingsBefore matching the samples, analyses revealed children attending Place2Be's counselling services were significantly more likely to be boys (56.6% vs. 51.1%), of ethnic minority origin (46.4% vs. 21.5%), eligible for free school meals (FSM; 52.7% vs. 16.9%) and have special educational needs and disabilities (SEND) status (43.1% vs. 21.1%) than the comparison group. They also had lower academic attainment than children who were not in counselling. However, after a coarsened exact matching on relevant background characteristics, the Place2Be sample was found to have similar levels of academic progress to the matched national sample, suggesting they did not fall behind similar children.ConclusionsFindings indicate that individual school‐based counselling may be helpful as a potential intervention for supporting vulnerable children's (defined as those identified by schools or parents as in need of individual counselling) academic progress in primary schools, as well as socio‐emotional outcomes; however, further research is needed.
Regulatory mechanisms underlying interleukin‐6 expression in murine brown adipocytes
Authors: Fu Xiajie , Murakami Masaru , Hashimoto Osamu , Matsui Tohru , Funaba Masayuki 
Published: January 2024

AbstractThree types of adipocytes, white, brown, and beige, regulate the systemic energy balance through the storage and expenditure of chemical energy. In addition, adipocytes produce various bioactive molecules known as adipokines. In contrast to white adipocyte‐derived molecules, less information is available on the adipokines produced by brown adipocytes (batokine). This study explored the regulatory expression of interleukin (IL)‐6 in cell culture studies. Norepinephrine or a nonselective β‐adrenergic receptor agonist increased the expression of IL‐6 in primary brown adipocytes and HB2 brown adipocytes. Treatment with forskolin (Fsk), an activator of the cAMP‐dependent protein kinase (PKA) pathway (downstream signaling of the β‐adrenergic receptor), efficiently stimulated IL‐6 expression in brown adipocytes and myotubes. Phosphorylated CREB and phosphorylated p38 MAP kinase levels were increased in Fsk‐treated brown adipocytes within 5 min. In contrast, a long‐term (∼60 min and ∼4 h) treatment with Fsk was required for increase in STAT3 phosphorylation and C/EBPβ expression, respectively. The PKA, p38 MAP kinase, STAT3, and C/EBPβ pathways are required for the maximal IL‐6 expression induced by Fsk, which were verified by use of various inhibitors of these signal pathways. Vitamin C enhanced Fsk‐induced IL‐6 expression through the extracellular signal‐regulated kinase activity. The present study provides basic information on the regulatory expression of IL‐6 in activated brown adipocytes.
Insights into cAMP‐dependent molecular mechanisms regulating expression and function of LGALS16 gene in choriocarcinoma JEG‐3 cells
Authors: Kaminker Jennifer D. , Butt Ahmad G. , Killeen Hailey , Timoshenko Alexander V. 
Published: January 2024

AbstractThe human choriocarcinoma cell line JEG‐3 offers a valuable model to study galectin‐16 gene (LGALS16) expression and functions in the context of placental cell differentiation and cancer cell biology. Recent evidence indicates that cAMP‐mediated signaling pathways might be responsible for the upregulation of LGALS16; however, the underlying mechanisms are unknown. Here, we employed biochemical inhibitors of the cAMP cascade and CRISPR/Cas9 engineered cells to assess regulatory patterns and associations between cAMP‐induced trophoblast differentiation and LGALS16 expression in JEG‐3 cells. The expression of LGALS16 was significantly upregulated in parallel with human chorionic gonadotropin beta (CGB), a biomarker of syncytiotrophoblast differentiation, in response to 8‐Br‐cAMP. Inhibition of p38 MAPK and EPAC significantly altered LGALS16 expression during differentiation, while PKA inhibition failed to change LGALS16 and CGB3/5 expression in our cell model. The CRISPR/Cas9 LGALS16 knockout cell pool expressed a significantly lower amount of CGB3/5, a reduced level of CGB protein, and an unaltered cell growth rate in response to 8‐Br‐cAMP in comparison with wild‐type JEG‐3 cells. Collectively, these findings suggest that LGALS16 is required for the trophoblast‐like differentiation of JEG‐3 cells, and its expression is mediated through p38 MAPK and EPAC signaling pathway branches.
A systematic scoping review exploring how people with lived experience have been involved in prison and forensic mental health research
Authors: Rutherford Rosie , Bowes Nicola , Cornwell Rosie , Heggs Daniel , Pashley Susannah 
Published: January 2024

AbstractBackgroundIntroduction of guidance by the National Institute for Health Research has led to an increase in participation by people with ‘lived experience’ of mental health problems. However, some researchers have questioned the extent to which involvement has been meaningful, expressing concerns that involvement is impeded by the structure and culture of academia. A prior review of literature to 2016 provided little evidence of active engagement.AimsTo find out from published literature how patient and public involvement in designing and or conducting research has been used in forensic mental health settings, prisons or probation since the last review period.MethodsA systematic scoping review of research published in academic journals between 2016 and February 2023 was completed using terms for research activity, involvement of people with experience of receiving services and health or justice systems to search three databases: MEDLINE, EMBASE and PsycINFO. We used the Guidance for Reporting Patient and Public Involvement in Research Tool to support data extraction and to summarise our own service user involvement in this study.ResultsFrom 675 unique titles retrieved, 17 were eligible for inclusion, covering 16 unique studies. Most of the included research was by/with people who had prison experience. Only two studies had been conducted by/with people who had experience of secure hospital wards/forensic mental health services. Details of how people with lived experience had contributed to the research were scarce, but in 8 studies they had been involved throughout and included in the authorship group.ConclusionWhilst this review identifies pockets of good practice, meaningful engagement in forensic mental health research seems to remain rare, at least as reported in papers published in academic journals. Further research is required into whether this reflects real limits on inclusion, as we suspect, or such full integration that such reporting is not regarded as necessary or desirable, which we doubt. We urge journal editors to routinely ask authors to include information about how people with lived experience have been involved in any published research and the nature and extent of the influence they had. This may help to develop the evidence base and guard against tokenistic involvement.
Comprehensive clinical outcomes of drug‐coated balloon treatment for coronary artery disease. Insights from a single‐center experience
Authors: Funatsu Atsushi , Sato Tatsushi , Koike Jumpei , Mizobuchi Masahiro , Kobayashi Tomoko , Nakamura Shigeru 
Published: January 2024

AbstractBackgroundSome clinical trials have verified the efficacy and safety of paclitaxel drug‐coated balloon (DCB) for small vessel coronary artery disease. However, nonsmall vessel and calcified lesions received less attention.AimsThis study aimed to investigate the efficacy of DCB treatment for various types of coronary artery lesions, including not only small vessel disease but also nonsmall vessel disease and calcified lesions. In this real‐world clinical practice study, in‐stent restenosis was excluded.MethodsThis study consecutively included 934 patients with 1751 nonstented lesions who received DCB at a cardiovascular center in Kyoto Katsura Hospital in Japan between 2009 and 2012 and 2014 to 2019. This study enrolled and retrospectively analyzed all of the patients. Eligible patients routinely underwent follow‐up angiography at 6–8 months after percutaneous coronary intervention. The primary endpoint includes target lesion revascularization (TLR) during follow‐up. Further, this study calculated the predictor of TLR using multivariate analysis.ResultsThis study included the lesions involving 46.4% of type B2/C, 26.9% with severe calcification, and 6.0% with DCB restenosis. Mean DCB diameter and length were 2.75 ± 0.51 mm and 24.2 ± 9.6 mm, respectively. The median follow‐up duration was 18 months. Follow‐up angiography revealed a TLR rate of 9% and a restenosis rate of 9%. This study identified hemodialysis and current smoking as independent TLR predictors.ConclusionIn routine clinical practice, the effectiveness of DCB was observed consistently across various types of coronary artery disease.
The psychiatric symptoms in anti‐IgLON5 disease: Case report and literature review
Authors: Luo Yuanyuan , Xiao Jun , Li Jieying 
Published: January 2024

Key Clinical MessageImmunotherapy may be ineffective in the advanced stages of anti‐IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti‐IgLON5 disease may be associated with neurodegeneration.
FGF23‐related hypophosphatemic rickets preceding the onset of systemic lupus erythematosus: A juvenile case
Authors: tabei Yoko , Ohtsu Yoshiaki , Shimada Masaharu , Wada Aya , Hamajima Emi , Osawa Yoshimitsu , Takizawa Takumi 
Published: January 2024

Key Clinical MessageThis case report describes the clinical course of a juvenile female with FGF23‐related hypophosphatemic rickets preceding the onset of SLE. Our study demonstrates the possibility of hypophosphatemic rickets as an early symptom of SLE.AbstractFibroblast growth factor 23 (FGF23)‐related hypophosphatemic rickets is observed in both genetic and acquired disorders. Various reports describe FGF23‐related hypophosphatemia with systemic lupus erythematosus (SLE), although FGF23‐related hypophosphatemia preceding the onset of SLE has never been described. Here, we report the case of a 9‐year‐old female with FGF23‐related hypophosphatemic rickets preceding the onset of SLE. The patient presented to us with arthralgia in the lower extremities and abnormality of gait lasting for 8 months. She was diagnosed with FGF23 hypophosphatemic rickets due to the presence of hypophosphatemic rickets symptoms and high serum levels of FGF23. Additional examination excluded hereditary diseases and tumor‐induced osteomalacia. Three months after diagnosis of FGF23‐related hypophosphatemic rickets, she developed nephritis and was diagnosed with SLE. She was treated with prednisolone, hemodialysis, and disease‐modifying drugs, as well as oral sodium phosphate to improve hypophosphatemia. Serum anti‐double‐stranded DNA antibody (dsDNAab) and plasma tumor necrosis factor‐α (TNF‐α) were elevated at FGF23‐related hypophosphatemic rickets diagnosis. During the clinical course, serum FGF23 correlated with dsDNAab and TNF‐α serum levels, which are involved in SLE disease activity. In this case, FGF23‐related hypophosphatemic rickets without hereditary diseases or tumor‐induced osteomalacia occurred before the appearance of juvenile SLE symptoms, and serum FGF23 represented disease activity in SLE.
Systemic pain relief after omalizumab injection in patient with hypermobile Ehlers–Danlos syndrome: A case report
Authors: Jonik Sarahrose , Rothka Andrew Joseph , Cherin Neyha 
Published: January 2024

Key Clinical MessageOmalizumab may be a beneficial adjunct treatment option for hEDS patients require to improve pain control, ability to perform ADLs and functionality and social engagement, and most importantly, quality of life.
Photocatalytic Structures for Protein Modifications
Authors: Liu Zhengyi , Okamoto Yasunori , Sato Shinichi 
Published: January 2024

AbstractThe chemical modification of proteins serves as a fundamental tool for understanding biological processes and enables the design of biofunctional materials. Among the available methodologies, photochemical strategies have garnered significant attention because of their remarkable biocompatibility and precise spatiotemporal reaction control. Developing novel reactions tailored to specific applications necessitates a comprehensive understanding of photoreactive properties, including catalyst structures, appropriate modifiers, and reaction conditions. This review discusses chemical modifications of proteins using an array of catalysts, including photoredox catalysts for single‐electron transfer (SET), catalysts for energy transfer, long‐wavelength excitable photocatalysts, genetically encoded photocatalysts, and artificial metalloenzymes. The discussion covers the unique attributes, mechanisms, practical applications, and future prospects of each catalyst‐driven reaction, shedding light on the evolving landscape of protein chemical modifications.